Biopharmaceutical developers should introduce risk-based, phase-appropriate characterization strategies for quality control ...
Companies organised outside the US need to be aware of potential proposals to change the definition of “foreign private ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results